Loading…
COVID‐19 and Older Adults: What We Know
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), a novel virus that causes COVID‐19 infection, has recently emerged and caused a deadly pandemic. Studies have shown that this virus causes worse outcomes and a higher mortality rate in older adults and those with comorbidities such as hyp...
Saved in:
| Published in: | Journal of the American Geriatrics Society 2020-05, Vol.68 (5), p.926-929 |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Request full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c5372-e71352b528a85251ab488773acfc50df580a18552806a59af454a56c69f7051e3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c5372-e71352b528a85251ab488773acfc50df580a18552806a59af454a56c69f7051e3 |
| container_end_page | 929 |
| container_issue | 5 |
| container_start_page | 926 |
| container_title | Journal of the American Geriatrics Society |
| container_volume | 68 |
| creator | Shahid, Zainab Kalayanamitra, Ricci McClafferty, Brendan Kepko, Douglas Ramgobin, Devyani Patel, Ravi Aggarwal, Chander Shekher Vunnam, Ramarao Sahu, Nitasa Bhatt, Dhirisha Jones, Kirk Golamari, Reshma Jain, Rohit |
| description | Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), a novel virus that causes COVID‐19 infection, has recently emerged and caused a deadly pandemic. Studies have shown that this virus causes worse outcomes and a higher mortality rate in older adults and those with comorbidities such as hypertension, cardiovascular disease, diabetes, chronic respiratory disease, and chronic kidney disease (CKD). A significant percentage of older American adults have these diseases, putting them at a higher risk of infection. Additionally, many adults with hypertension, diabetes, and CKD are placed on angiotensin‐converting enzyme (ACE) inhibitors and angiotensin II receptor blockers. Studies have shown that these medications upregulate the ACE‐2 receptor, the very receptor that the SARS‐CoV‐2 virus uses to enter host cells. Although it has been hypothesized that this may cause a further increased risk of infection, more studies on the role of these medications in COVID‐19 infections are necessary. In this review, we discuss the transmission, symptomatology, and mortality of COVID‐19 as they relate to older adults, and possible treatments that are currently under investigation. J Am Geriatr Soc 68:926–929, 2020 |
| doi_str_mv | 10.1111/jgs.16472 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_COVID</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7262251</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2387255747</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5372-e71352b528a85251ab488773acfc50df580a18552806a59af454a56c69f7051e3</originalsourceid><addsrcrecordid>eNp9kctOwkAUhidGI4gufAHTxI0sCnPp6UxdmBBURElYeGE5GdoplpQWO1TCzkfwGX0SR4tETfRszuJ8-XL-_AgdEtwidtrTiWkR3-N0C9UJMOqCR2Ab1THG1BU-8Wpoz5gpxoRiIXZRjVEKAJjXUbM7fOifv728ksBRWeQM00gXTicq04U5dUaPauGMtHOT5ct9tBOr1OiD9W6g-8uLu-6VOxj2-t3OwA2BcepqThjQMVChBFAgauwJwTlTYRwCjmIQWBEB9o59BYGKPfAU-KEfxBwD0ayBzirvvBzPdBTqbFGoVM6LZKaKlcxVIn9esuRRTvJnyalvYxErOFkLivyp1GYhZ4kJdZqqTOelkZQJbuNzj1v0-Bc6zcsis_Ek9TDjnPsU_qVYIAIsfC4s1ayosMiNKXS8eZlg-VGTtDXJz5ose_Q944b86sUC7QpYJqle_W2S173bSvkOE6SX6g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2398908678</pqid></control><display><type>article</type><title>COVID‐19 and Older Adults: What We Know</title><source>Coronavirus Research Database</source><creator>Shahid, Zainab ; Kalayanamitra, Ricci ; McClafferty, Brendan ; Kepko, Douglas ; Ramgobin, Devyani ; Patel, Ravi ; Aggarwal, Chander Shekher ; Vunnam, Ramarao ; Sahu, Nitasa ; Bhatt, Dhirisha ; Jones, Kirk ; Golamari, Reshma ; Jain, Rohit</creator><creatorcontrib>Shahid, Zainab ; Kalayanamitra, Ricci ; McClafferty, Brendan ; Kepko, Douglas ; Ramgobin, Devyani ; Patel, Ravi ; Aggarwal, Chander Shekher ; Vunnam, Ramarao ; Sahu, Nitasa ; Bhatt, Dhirisha ; Jones, Kirk ; Golamari, Reshma ; Jain, Rohit</creatorcontrib><description>Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), a novel virus that causes COVID‐19 infection, has recently emerged and caused a deadly pandemic. Studies have shown that this virus causes worse outcomes and a higher mortality rate in older adults and those with comorbidities such as hypertension, cardiovascular disease, diabetes, chronic respiratory disease, and chronic kidney disease (CKD). A significant percentage of older American adults have these diseases, putting them at a higher risk of infection. Additionally, many adults with hypertension, diabetes, and CKD are placed on angiotensin‐converting enzyme (ACE) inhibitors and angiotensin II receptor blockers. Studies have shown that these medications upregulate the ACE‐2 receptor, the very receptor that the SARS‐CoV‐2 virus uses to enter host cells. Although it has been hypothesized that this may cause a further increased risk of infection, more studies on the role of these medications in COVID‐19 infections are necessary. In this review, we discuss the transmission, symptomatology, and mortality of COVID‐19 as they relate to older adults, and possible treatments that are currently under investigation. J Am Geriatr Soc 68:926–929, 2020</description><identifier>ISSN: 0002-8614</identifier><identifier>EISSN: 1532-5415</identifier><identifier>DOI: 10.1111/jgs.16472</identifier><identifier>PMID: 32255507</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Aged ; Angiotensin II ; Angiotensin-converting enzyme inhibitors ; Betacoronavirus ; Cardiovascular diseases ; coronavirus ; Coronavirus Infections - diagnosis ; Coronavirus Infections - mortality ; Coronavirus Infections - physiopathology ; Coronavirus Infections - therapy ; Coronaviruses ; COVID-19 ; COVID‐19‐Related Content ; Diabetes ; Diabetes mellitus ; Disease ; Humans ; Hypertension ; Infections ; Kidney diseases ; Mortality ; Non-Randomized Controlled Trials as Topic ; older adults ; Older people ; Pandemics ; Pneumonia, Viral - diagnosis ; Pneumonia, Viral - mortality ; Pneumonia, Viral - physiopathology ; Pneumonia, Viral - therapy ; Respiratory diseases ; Review ; Risk Factors ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2</subject><ispartof>Journal of the American Geriatrics Society, 2020-05, Vol.68 (5), p.926-929</ispartof><rights>2020 The American Geriatrics Society</rights><rights>2020 The American Geriatrics Society.</rights><rights>2020. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://novel-coronavirus.onlinelibrary.wiley.com</rights><rights>2020 American Geriatrics Society and Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5372-e71352b528a85251ab488773acfc50df580a18552806a59af454a56c69f7051e3</citedby><cites>FETCH-LOGICAL-c5372-e71352b528a85251ab488773acfc50df580a18552806a59af454a56c69f7051e3</cites><orcidid>0000-0002-0716-8338 ; 0000-0002-4767-9095</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjgs.16472$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2398908678?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,315,786,790,891,27957,27958,38551,43930,50923,51032</link.rule.ids><linktorsrc>$$Uhttps://www.proquest.com/docview/2398908678/abstract/?pq-origsite=primo$$EView_record_in_ProQuest$$FView_record_in_$$GProQuest</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32255507$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shahid, Zainab</creatorcontrib><creatorcontrib>Kalayanamitra, Ricci</creatorcontrib><creatorcontrib>McClafferty, Brendan</creatorcontrib><creatorcontrib>Kepko, Douglas</creatorcontrib><creatorcontrib>Ramgobin, Devyani</creatorcontrib><creatorcontrib>Patel, Ravi</creatorcontrib><creatorcontrib>Aggarwal, Chander Shekher</creatorcontrib><creatorcontrib>Vunnam, Ramarao</creatorcontrib><creatorcontrib>Sahu, Nitasa</creatorcontrib><creatorcontrib>Bhatt, Dhirisha</creatorcontrib><creatorcontrib>Jones, Kirk</creatorcontrib><creatorcontrib>Golamari, Reshma</creatorcontrib><creatorcontrib>Jain, Rohit</creatorcontrib><title>COVID‐19 and Older Adults: What We Know</title><title>Journal of the American Geriatrics Society</title><addtitle>J Am Geriatr Soc</addtitle><description>Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), a novel virus that causes COVID‐19 infection, has recently emerged and caused a deadly pandemic. Studies have shown that this virus causes worse outcomes and a higher mortality rate in older adults and those with comorbidities such as hypertension, cardiovascular disease, diabetes, chronic respiratory disease, and chronic kidney disease (CKD). A significant percentage of older American adults have these diseases, putting them at a higher risk of infection. Additionally, many adults with hypertension, diabetes, and CKD are placed on angiotensin‐converting enzyme (ACE) inhibitors and angiotensin II receptor blockers. Studies have shown that these medications upregulate the ACE‐2 receptor, the very receptor that the SARS‐CoV‐2 virus uses to enter host cells. Although it has been hypothesized that this may cause a further increased risk of infection, more studies on the role of these medications in COVID‐19 infections are necessary. In this review, we discuss the transmission, symptomatology, and mortality of COVID‐19 as they relate to older adults, and possible treatments that are currently under investigation. J Am Geriatr Soc 68:926–929, 2020</description><subject>Aged</subject><subject>Angiotensin II</subject><subject>Angiotensin-converting enzyme inhibitors</subject><subject>Betacoronavirus</subject><subject>Cardiovascular diseases</subject><subject>coronavirus</subject><subject>Coronavirus Infections - diagnosis</subject><subject>Coronavirus Infections - mortality</subject><subject>Coronavirus Infections - physiopathology</subject><subject>Coronavirus Infections - therapy</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID‐19‐Related Content</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Disease</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Infections</subject><subject>Kidney diseases</subject><subject>Mortality</subject><subject>Non-Randomized Controlled Trials as Topic</subject><subject>older adults</subject><subject>Older people</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - diagnosis</subject><subject>Pneumonia, Viral - mortality</subject><subject>Pneumonia, Viral - physiopathology</subject><subject>Pneumonia, Viral - therapy</subject><subject>Respiratory diseases</subject><subject>Review</subject><subject>Risk Factors</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><issn>0002-8614</issn><issn>1532-5415</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><recordid>eNp9kctOwkAUhidGI4gufAHTxI0sCnPp6UxdmBBURElYeGE5GdoplpQWO1TCzkfwGX0SR4tETfRszuJ8-XL-_AgdEtwidtrTiWkR3-N0C9UJMOqCR2Ab1THG1BU-8Wpoz5gpxoRiIXZRjVEKAJjXUbM7fOifv728ksBRWeQM00gXTicq04U5dUaPauGMtHOT5ct9tBOr1OiD9W6g-8uLu-6VOxj2-t3OwA2BcepqThjQMVChBFAgauwJwTlTYRwCjmIQWBEB9o59BYGKPfAU-KEfxBwD0ayBzirvvBzPdBTqbFGoVM6LZKaKlcxVIn9esuRRTvJnyalvYxErOFkLivyp1GYhZ4kJdZqqTOelkZQJbuNzj1v0-Bc6zcsis_Ek9TDjnPsU_qVYIAIsfC4s1ayosMiNKXS8eZlg-VGTtDXJz5ose_Q944b86sUC7QpYJqle_W2S173bSvkOE6SX6g</recordid><startdate>202005</startdate><enddate>202005</enddate><creator>Shahid, Zainab</creator><creator>Kalayanamitra, Ricci</creator><creator>McClafferty, Brendan</creator><creator>Kepko, Douglas</creator><creator>Ramgobin, Devyani</creator><creator>Patel, Ravi</creator><creator>Aggarwal, Chander Shekher</creator><creator>Vunnam, Ramarao</creator><creator>Sahu, Nitasa</creator><creator>Bhatt, Dhirisha</creator><creator>Jones, Kirk</creator><creator>Golamari, Reshma</creator><creator>Jain, Rohit</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>COVID</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0716-8338</orcidid><orcidid>https://orcid.org/0000-0002-4767-9095</orcidid></search><sort><creationdate>202005</creationdate><title>COVID‐19 and Older Adults: What We Know</title><author>Shahid, Zainab ; Kalayanamitra, Ricci ; McClafferty, Brendan ; Kepko, Douglas ; Ramgobin, Devyani ; Patel, Ravi ; Aggarwal, Chander Shekher ; Vunnam, Ramarao ; Sahu, Nitasa ; Bhatt, Dhirisha ; Jones, Kirk ; Golamari, Reshma ; Jain, Rohit</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5372-e71352b528a85251ab488773acfc50df580a18552806a59af454a56c69f7051e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Angiotensin II</topic><topic>Angiotensin-converting enzyme inhibitors</topic><topic>Betacoronavirus</topic><topic>Cardiovascular diseases</topic><topic>coronavirus</topic><topic>Coronavirus Infections - diagnosis</topic><topic>Coronavirus Infections - mortality</topic><topic>Coronavirus Infections - physiopathology</topic><topic>Coronavirus Infections - therapy</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID‐19‐Related Content</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Disease</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Infections</topic><topic>Kidney diseases</topic><topic>Mortality</topic><topic>Non-Randomized Controlled Trials as Topic</topic><topic>older adults</topic><topic>Older people</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - diagnosis</topic><topic>Pneumonia, Viral - mortality</topic><topic>Pneumonia, Viral - physiopathology</topic><topic>Pneumonia, Viral - therapy</topic><topic>Respiratory diseases</topic><topic>Review</topic><topic>Risk Factors</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shahid, Zainab</creatorcontrib><creatorcontrib>Kalayanamitra, Ricci</creatorcontrib><creatorcontrib>McClafferty, Brendan</creatorcontrib><creatorcontrib>Kepko, Douglas</creatorcontrib><creatorcontrib>Ramgobin, Devyani</creatorcontrib><creatorcontrib>Patel, Ravi</creatorcontrib><creatorcontrib>Aggarwal, Chander Shekher</creatorcontrib><creatorcontrib>Vunnam, Ramarao</creatorcontrib><creatorcontrib>Sahu, Nitasa</creatorcontrib><creatorcontrib>Bhatt, Dhirisha</creatorcontrib><creatorcontrib>Jones, Kirk</creatorcontrib><creatorcontrib>Golamari, Reshma</creatorcontrib><creatorcontrib>Jain, Rohit</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Coronavirus Research Database</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of the American Geriatrics Society</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Shahid, Zainab</au><au>Kalayanamitra, Ricci</au><au>McClafferty, Brendan</au><au>Kepko, Douglas</au><au>Ramgobin, Devyani</au><au>Patel, Ravi</au><au>Aggarwal, Chander Shekher</au><au>Vunnam, Ramarao</au><au>Sahu, Nitasa</au><au>Bhatt, Dhirisha</au><au>Jones, Kirk</au><au>Golamari, Reshma</au><au>Jain, Rohit</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID‐19 and Older Adults: What We Know</atitle><jtitle>Journal of the American Geriatrics Society</jtitle><addtitle>J Am Geriatr Soc</addtitle><date>2020-05</date><risdate>2020</risdate><volume>68</volume><issue>5</issue><spage>926</spage><epage>929</epage><pages>926-929</pages><issn>0002-8614</issn><eissn>1532-5415</eissn><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-3</notes><notes>content type line 23</notes><notes>ObjectType-Review-1</notes><abstract>Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), a novel virus that causes COVID‐19 infection, has recently emerged and caused a deadly pandemic. Studies have shown that this virus causes worse outcomes and a higher mortality rate in older adults and those with comorbidities such as hypertension, cardiovascular disease, diabetes, chronic respiratory disease, and chronic kidney disease (CKD). A significant percentage of older American adults have these diseases, putting them at a higher risk of infection. Additionally, many adults with hypertension, diabetes, and CKD are placed on angiotensin‐converting enzyme (ACE) inhibitors and angiotensin II receptor blockers. Studies have shown that these medications upregulate the ACE‐2 receptor, the very receptor that the SARS‐CoV‐2 virus uses to enter host cells. Although it has been hypothesized that this may cause a further increased risk of infection, more studies on the role of these medications in COVID‐19 infections are necessary. In this review, we discuss the transmission, symptomatology, and mortality of COVID‐19 as they relate to older adults, and possible treatments that are currently under investigation. J Am Geriatr Soc 68:926–929, 2020</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>32255507</pmid><doi>10.1111/jgs.16472</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-0716-8338</orcidid><orcidid>https://orcid.org/0000-0002-4767-9095</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 0002-8614 |
| ispartof | Journal of the American Geriatrics Society, 2020-05, Vol.68 (5), p.926-929 |
| issn | 0002-8614 1532-5415 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7262251 |
| source | Coronavirus Research Database |
| subjects | Aged Angiotensin II Angiotensin-converting enzyme inhibitors Betacoronavirus Cardiovascular diseases coronavirus Coronavirus Infections - diagnosis Coronavirus Infections - mortality Coronavirus Infections - physiopathology Coronavirus Infections - therapy Coronaviruses COVID-19 COVID‐19‐Related Content Diabetes Diabetes mellitus Disease Humans Hypertension Infections Kidney diseases Mortality Non-Randomized Controlled Trials as Topic older adults Older people Pandemics Pneumonia, Viral - diagnosis Pneumonia, Viral - mortality Pneumonia, Viral - physiopathology Pneumonia, Viral - therapy Respiratory diseases Review Risk Factors SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 |
| title | COVID‐19 and Older Adults: What We Know |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T17%3A49%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_COVID&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID%E2%80%9019%20and%20Older%20Adults:%20What%20We%20Know&rft.jtitle=Journal%20of%20the%20American%20Geriatrics%20Society&rft.au=Shahid,%20Zainab&rft.date=2020-05&rft.volume=68&rft.issue=5&rft.spage=926&rft.epage=929&rft.pages=926-929&rft.issn=0002-8614&rft.eissn=1532-5415&rft_id=info:doi/10.1111/jgs.16472&rft_dat=%3Cproquest_COVID%3E2387255747%3C/proquest_COVID%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5372-e71352b528a85251ab488773acfc50df580a18552806a59af454a56c69f7051e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2398908678&rft_id=info:pmid/32255507&rfr_iscdi=true |